CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (AMEX: IDP) today reported financial results for the three and six months ended June 30, 2007. “Our financial results for the second quarter reflect continued execution of our business strategy to advance our development programs with our lead candidates, IMO-2055 and IMO-2125, to evaluate novel Toll-Like Receptor (TLR) antagonists and TLR7, 8 and 9 agonists in preclinical models, and to support our collaborations with Novartis and Merck & Co., Inc.,” said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer of Idera.
